Eledon Pharmaceuticals, Inc. (ELDN)
1.78
-0.12
(-6.32%)
USD |
NASDAQ |
Nov 20, 16:00
1.81
+0.03
(+1.69%)
After-Hours: 20:00
Eledon Pharmaceuticals Enterprise Value : 114.69M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 114.69M |
| November 19, 2026 | 124.46M |
| November 18, 2026 | 135.05M |
| November 17, 2026 | 130.98M |
| November 16, 2026 | 130.16M |
| November 13, 2026 | 141.97M |
| November 12, 2026 | 162.33M |
| November 11, 2026 | 187.17M |
| November 10, 2026 | 194.50M |
| November 09, 2026 | 203.46M |
| November 06, 2026 | 181.88M |
| November 05, 2026 | 170.07M |
| November 04, 2026 | 189.62M |
| November 03, 2026 | 183.10M |
| November 02, 2026 | 183.10M |
| October 30, 2026 | 195.32M |
| October 29, 2026 | 217.31M |
| October 28, 2026 | 194.50M |
| October 27, 2026 | 166.00M |
| October 26, 2026 | 149.71M |
| October 23, 2026 | 157.04M |
| October 22, 2026 | 157.04M |
| October 21, 2026 | 153.78M |
| October 20, 2026 | 153.37M |
| October 19, 2026 | 145.64M |
| Date | Value |
|---|---|
| October 16, 2026 | 143.19M |
| October 15, 2026 | 154.60M |
| October 14, 2026 | 152.97M |
| October 13, 2026 | 160.30M |
| October 12, 2026 | 168.44M |
| October 09, 2026 | 171.70M |
| October 08, 2026 | 166.81M |
| October 07, 2026 | 166.81M |
| October 06, 2026 | 169.26M |
| October 05, 2026 | 173.33M |
| October 02, 2026 | 172.51M |
| October 01, 2026 | 168.03M |
| September 30, 2026 | 175.77M |
| September 29, 2026 | 152.96M |
| September 28, 2026 | 164.28M |
| September 25, 2026 | 165.09M |
| September 24, 2026 | 167.52M |
| September 23, 2026 | 170.75M |
| September 22, 2026 | 184.51M |
| September 21, 2026 | 168.33M |
| September 18, 2026 | 162.66M |
| September 17, 2026 | 165.09M |
| September 16, 2026 | 166.71M |
| September 15, 2026 | 169.94M |
| September 14, 2026 | 174.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.933M |
| Total Expenses (Quarterly) | 3.933M |
| EPS Diluted (Quarterly) | -0.0343 |
| Earnings Yield | -44.85% |
| Normalized Earnings Yield | -46.21 |